INT97133

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2001
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 17
Disease Relevance 11.97
Pain Relevance 1.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CD83) plasma membrane (CD83)
Anatomy Link Frequency
CD86 9
PDL-1 1
blood 1
dendritic cells 1
CD83 (Homo sapiens)
Pain Link Frequency Relevance Heat
chemokine 106 98.34 Very High Very High Very High
Chronic pancreatitis 150 96.00 Very High Very High Very High
Inflammation 512 90.72 High High
cytokine 20 87.52 High High
Potency 2 39.08 Quite Low
cINOD 16 5.00 Very Low Very Low Very Low
rheumatoid arthritis 15 5.00 Very Low Very Low Very Low
dexamethasone 5 5.00 Very Low Very Low Very Low
Central nervous system 2 5.00 Very Low Very Low Very Low
tolerance 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adenocarcinoma 1350 99.92 Very High Very High Very High
Breast Cancer 60 99.10 Very High Very High Very High
Disease 77 98.96 Very High Very High Very High
Hepatitis C Virus Infection 30 98.88 Very High Very High Very High
Pancreatitis 150 96.00 Very High Very High Very High
Autoimmune Disease 35 95.72 Very High Very High Very High
INFLAMMATION 513 90.72 High High
Leukemia 15 88.60 High High
Brain Tumor 10 88.16 High High
Hepatocellular Cancer 15 87.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In distinction to drug-free maturing dendritic cells, 2.5 micromol/L sulfasalazine upregulated the levels of CD14 and CD68 and downregulated the levels of CD40, CD80, and CD83 (for all CD markers, p<0.03 for difference between measurements in the absence and the presence of sulfasalazine).
Positive_regulation (upregulated) of CD83 in dendritic cells
1) Confidence 0.42 Published 2001 Journal Croat. Med. J. Section Body Doc Link 11471196 Disease Relevance 0 Pain Relevance 0
When MDCs and PDCs undergo phenotypic maturation certain factors, for instance CD83, CD40, HLA DR, B7H3 (CD276) and CCR7 are upregulated, whereas DCIR, ICOSL (CD275) [18], and several tissue retaining chemokine receptors (CCR1, CCR2, CCR3, CCR5 and, CCR8) are down modulated and as a consequence the DCs will migrate to the local lymphatic tissue [19], [20], [21].
Positive_regulation (upregulated) of CD83 associated with chemokine
2) Confidence 0.40 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.58 Pain Relevance 0.15
In breast cancer, blood DC exhibit an altered phenotype with increased level of CD83 and this correlated with disease severity [22].
Positive_regulation (increased) of CD83 in blood associated with breast cancer and disease
3) Confidence 0.40 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 1.20 Pain Relevance 0.07
The CD83, CD40 and CD86 are upregulated as a step in the maturation process and have a role in immune modulation [38].
Positive_regulation (upregulated) of CD83 in CD86
4) Confidence 0.40 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 1.16 Pain Relevance 0.16
CD83 is a glycoprotein that is upregulated together with costimulatory molecules, such as CD40 and CD86, thus suggesting a role in the induction of immune responses [38].
Positive_regulation (upregulated) of CD83 in CD86
5) Confidence 0.40 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.83 Pain Relevance 0.05
Mature DCs express high levels of Class I and Class II molecules, altered chemokine and galectin family (Dietz et al 2000; Bax et al 2007) expression, co-stimulatory markers CD80 and CD86, and the immunoglobulin CD83 (Zhou and Tedder 1995).
Positive_regulation (markers) of CD83 in CD86 associated with chemokine
6) Confidence 0.32 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727883 Disease Relevance 0.30 Pain Relevance 0.09
The TLR9 ligation on PDCs induced a mature phenotype with upregulation of CD40, CD83, CD86, CCR7, PDL-1, ICOSL and CCR5 and decreased B7H3 and DCIR (Figure 9).
Positive_regulation (upregulation) of CD83 in PDL-1
7) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.30 Pain Relevance 0.03
MDCs and PDCs had significantly increased levels of CD83 (MDC; p?
Positive_regulation (increased) of CD83
8) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 1.19 Pain Relevance 0.53
MDCs and PDCs from PDAC patients had increased levels of the maturation marker CD83 and the costimulatory molecule CD40
Positive_regulation (increased) of CD83 associated with adenocarcinoma
9) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.77 Pain Relevance 0.10
Increased levels of CD40 and CD83 were observed on PDCs from HCV infected patients [13], whereas MDCs were less affected [13].
Positive_regulation (Increased) of CD83 associated with hepatitis c virus infection
10) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 1.16 Pain Relevance 0.18
We observed that CD83 was significantly elevated both in MDCs (median 1.8%) and PDCs (median 2.8%) in patients with PDAC compared to control MDCs (median 0%) and PDCs (median 0%) (Figure 2A).
Positive_regulation (elevated) of CD83 associated with adenocarcinoma
11) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.73 Pain Relevance 0.04
Semi-mature profiles were seen for both MDCs and PDCs matured with PC021 plasma with significantly increased levels for CD40, CD83, CD86, and CCR7 on MDCs and enhanced levels of CD40, CD86, CD83, CCR7, and PDL-1 on PDCs (Figure 10B), which was a more clear activation than that achieved by pooled plasma.
Spec (clear) Positive_regulation (activation) of CD83 in CD86
12) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.72 Pain Relevance 0.06
Semi-mature profiles were seen for both MDCs and PDCs matured with PC021 plasma with significantly increased levels for CD40, CD83, CD86, and CCR7 on MDCs and enhanced levels of CD40, CD86, CD83, CCR7, and PDL-1 on PDCs (Figure 10B), which was a more clear activation than that achieved by pooled plasma.
Positive_regulation (increased) of CD83 in CD86
13) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.62 Pain Relevance 0.03
Semi-mature profiles were seen for both MDCs and PDCs matured with PC021 plasma with significantly increased levels for CD40, CD83, CD86, and CCR7 on MDCs and enhanced levels of CD40, CD86, CD83, CCR7, and PDL-1 on PDCs (Figure 10B), which was a more clear activation than that achieved by pooled plasma.
Positive_regulation (enhanced) of CD83 in CD86
14) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.60 Pain Relevance 0.03
Semi-mature profiles were seen for both MDCs and PDCs matured with PC021 plasma with significantly increased levels for CD40, CD83, CD86, and CCR7 on MDCs and enhanced levels of CD40, CD86, CD83, CCR7, and PDL-1 on PDCs (Figure 10B), which was a more clear activation than that achieved by pooled plasma.
Positive_regulation (increased) of CD83 in CD86
15) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.60 Pain Relevance 0.03
Semi-mature profiles were seen for both MDCs and PDCs matured with PC021 plasma with significantly increased levels for CD40, CD83, CD86, and CCR7 on MDCs and enhanced levels of CD40, CD86, CD83, CCR7, and PDL-1 on PDCs (Figure 10B), which was a more clear activation than that achieved by pooled plasma.
Positive_regulation (levels) of CD83 in CD86
16) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.62 Pain Relevance 0.03
Semi-mature profiles were seen for both MDCs and PDCs matured with PC021 plasma with significantly increased levels for CD40, CD83, CD86, and CCR7 on MDCs and enhanced levels of CD40, CD86, CD83, CCR7, and PDL-1 on PDCs (Figure 10B), which was a more clear activation than that achieved by pooled plasma.
Positive_regulation (levels) of CD83 in CD86
17) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.60 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox